PYLARIFY (piflufolastat F 18)
Prostate Cancer (Diagnostic Imaging)
Approved/CommercialMarketed
Key Facts
Indication
Prostate Cancer (Diagnostic Imaging)
Phase
Approved/Commercial
Status
Marketed
Company
About Lantheus Holdings
Lantheus Holdings is a pioneer in the radiopharmaceutical space, dedicated to transforming patient care through precision diagnostics and targeted radiotherapeutics. The company has achieved significant commercial success with its flagship product, PYLARIFY, a PSMA PET imaging agent for prostate cancer, and maintains a robust pipeline of next-generation diagnostic and therapeutic candidates. With a strong commercial infrastructure, deep manufacturing expertise, and strategic partnerships, Lantheus is strategically positioned to capitalize on the rapidly growing market for targeted radiopharmaceuticals in oncology and cardiology.
View full company profile